BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17348852)

  • 1. Flexible estrogen receptor modulators: synthesis, biochemistry and molecular modeling studies for 3-benzyl-4,6-diarylhex-3-ene and 3,4,6-triarylhex-3-ene derivatives.
    Smith HM; Knox AJ; Zisterer DM; Lloyd DG; Meegan MJ
    Med Chem; 2007 Mar; 3(2):135-55. PubMed ID: 17348852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
    Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
    Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis, structure-activity relationships and antagonistic effects in human MCF-7 breast cancer cells of flexible estrogen receptor modulators.
    Lloyd DG; Smith HM; O'Sullivan T; Zisterer DM; Meegan MJ
    Med Chem; 2005 Jul; 1(4):335-53. PubMed ID: 16789891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
    Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
    Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis, antiproliferative and pro-apoptotic activity of 2-phenylindoles.
    Kelly PM; Bright SA; Fayne D; Pollock JK; Zisterer DM; Williams DC; Meegan MJ
    Bioorg Med Chem; 2016 Sep; 24(18):4075-4099. PubMed ID: 27407030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells.
    Meegan MJ; Hughes RB; Lloyd DG; Williams DC; Zisterer DM
    J Med Chem; 2001 Mar; 44(7):1072-84. PubMed ID: 11297454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen Receptors.
    Lv W; Liu J; Skaar TC; O'Neill E; Yu G; Flockhart DA; Cushman M
    J Med Chem; 2016 Jan; 59(1):157-70. PubMed ID: 26704594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Solid-phase synthesis and investigation of benzofurans as selective estrogen receptor modulators.
    Smith RA; Chen J; Mader MM; Muegge I; Moehler U; Katti S; Marrero D; Stirtan WG; Weaver DR; Xiao H; Carley W
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2875-8. PubMed ID: 12270167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benzothiepin-derived molecular scaffolds for estrogen receptor modulators: synthesis and antagonistic effects in breast cancer cells.
    Meegan MJ; Barrett I; Zimmermann J; Knox AJ; Zisterer DM; Lloyd DG
    J Enzyme Inhib Med Chem; 2007 Oct; 22(5):655-66. PubMed ID: 18035834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells.
    Zheng Y; Wang C; Li C; Qiao J; Zhang F; Huang M; Ren W; Dong C; Huang J; Zhou HB
    Org Biomol Chem; 2012 Dec; 10(48):9689-99. PubMed ID: 23149805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NJK14013, a novel synthetic estrogen receptor-α agonist, exhibits estrogen receptor-independent, tumor cell-specific cytotoxicity.
    Kim HI; Kim T; Kim JE; Lee J; Heo J; Lee NR; Kim NJ; Inn KS
    Int J Oncol; 2015 Jul; 47(1):280-6. PubMed ID: 25964080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
    Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
    J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective estrogen receptor modulators with conformationally restricted side chains. Synthesis and structure-activity relationship of ERalpha-selective tetrahydroisoquinoline ligands.
    Renaud J; Bischoff SF; Buhl T; Floersheim P; Fournier B; Geiser M; Halleux C; Kallen J; Keller H; Ramage P
    J Med Chem; 2005 Jan; 48(2):364-79. PubMed ID: 15658851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first organometallic selective estrogen receptor modulators (SERMs) and their relevance to breast cancer.
    Jaouen G; Top S; Vessières A; Leclercq G; McGlinchey MJ
    Curr Med Chem; 2004 Sep; 11(18):2505-17. PubMed ID: 15379709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
    Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
    Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
    Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
    Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs).
    Musa MA; Khan MO; Cooperwood JS
    Curr Med Chem; 2007; 14(11):1249-61. PubMed ID: 17504144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of the anti-estrogenic activity of hydroxyl substituted diphenylnaphthyl alkene ligands for the estrogen receptor.
    Schmidt JM; Tremblay GB; Plastina MA; Ma F; Bhal neé Basra S; Feher M; Dunn-Dufault R; Redden PR
    Bioorg Med Chem; 2005 Mar; 13(5):1819-28. PubMed ID: 15776560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular mechanism of action at estrogen receptor alpha of a new clinically relevant antiestrogen (GW7604) related to tamoxifen.
    Bentrem D; Dardes R; Liu H; MacGregor-Schafer J; Zapf J; Jordan V
    Endocrinology; 2001 Feb; 142(2):838-46. PubMed ID: 11159857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nitric Oxide-Releasing Selective Estrogen Receptor Modulators: A Bifunctional Approach to Improve the Therapeutic Index.
    Bechmann N; Kniess T; Pietzsch J
    J Med Chem; 2019 Jul; 62(14):6525-6539. PubMed ID: 31099568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.